Castle Biosciences

139 articles with Castle Biosciences

• Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma

  1/20/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of clinical utility data for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC, for patients diagnosed with high-risk cutaneous SCC.

• Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019

  1/9/2020

  Q4 2019 DecisionDx-Melanoma test report volume increased 37% compared to Q4 2018

• Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology

  12/30/2019

  The results show that the DecisionDx-Melanoma test achieves a higher level of evidence than determined by major organizations that publish guidelines on melanoma management.

• Castle Biosciences Added to NASDAQ Biotechnology Index

  12/18/2019

  Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that the Company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to the market open on Monday, December 23, 2019.

• Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx

  12/3/2019

  Castle Biosciences, Inc. announced that its presentation at the Evercore ISI Second Annual HealthCONx Conference is now scheduled for 11:45 a.m. Eastern time on Thursday, December 5, 2019, in Boston.

• Castle Biosciences to Present at Upcoming Investor Conferences

  11/20/2019

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences

• Castle Biosciences Reports Third Quarter 2019 Results

  11/11/2019

  Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018

• Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk

  10/31/2019

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of results from a study validating a newly developed nomogram tool that combines information from the DecisionDx®-Melanoma test with clinicopathologic features to improve prediction of patients’ risk of melanoma recurrence.

• Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

  10/29/2019

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced the presentation of a development update and validation data for its cutaneous squamous cell carcinoma prognostic test, DecisionDx®-SCC.

• Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019

  10/28/2019

  Castle Biosciences, Inc. announced that it will release its financial results for the third quarter ended September 30, 2019, after the close of market on Monday, November 11, 2019.

• Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis

  10/28/2019

  Castle Biosciences, Inc. announced the presentation of data supporting clinical use of the DecisionDx®-Melanoma test to inform decisions of whether to discuss or recommend the sentinel lymph node biopsy, a surgical procedure used to provide additional prognostic information.

• Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node

  10/18/2019

  Castle Biosciences, Inc. announced the presentation of data supporting the ability of the DecisionDx®-Melanoma gene expression profile test to identify T1 melanoma patients at low risk for a positive sentinel lymph node at the American Society of Dermatopathology 56th Annual Meeting in San Diego from October 17-20.

• Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma

  10/16/2019

  Data presented at American Academy of Ophthalmology 2019 Annual Meeting

• Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma

  10/7/2019

  Study published recently in SKIN: The Journal of Cutaneous Medicine

• Castle Biosciences Added to Membership of US Small-Cap Russell 2000® Index

  9/19/2019

  The stock also was automatically added to the appropriate growth and value indexes.

• Castle Biosciences Announces Time Change for Presentation at the Baird 2019 Global Healthcare Conference

  9/4/2019

  Castle Biosciences, Inc. announced that its presentation at the Baird 2019 Global Healthcare Conference in New York City is now scheduled for 3:45 p.m. Eastern time on Wednesday, September 4, 2019.

• Castle Biosciences Reports Second Quarter 2019 Results

  9/3/2019

  Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2019.

• Castle Biosciences to Present at the Baird 2019 Global Healthcare Conference

  8/27/2019

  Castle Biosciences, Inc. announced that Derek Maetzold, President and Chief Executive Officer, is scheduled to present a company overview at the Baird 2019 Global Healthcare Conference in New York City on Wednesday, September 4, 2019, at 2:00 p.m. Eastern time.

• Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  7/29/2019

  Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the closing of its previously announced initial public offering of 4,600,000 shares of its common stock, which includes 600,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares

• Castle Biosciences Announces Pricing of Initial Public Offering at $16.00 per share.

  7/25/2019

  Castle Biosciences, Inc. announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $16.00 per share.